Journal of the National Cancer Institute最新文献_第8页

Response to Zhu, Bu, and Zhu. 对朱、布、朱的回应。

Journal of the National Cancer Institute Pub Date : 2025-07-23 DOI: 10.1093/jnci/djaf188

Annelie Johansson,Linda S Lindström

引用次数: 0

Assessing Outcomes Emerging After Conversion to Regular Approval for Cancer Drug Indications Granted Accelerated Approval, 1992-2021. 1992-2021年加速批准的癌症药物适应症转化为常规批准后的结果评估。

Journal of the National Cancer Institute Pub Date : 2025-07-21 DOI: 10.1093/jnci/djaf195

Ariadna Tibau,Alejandra Romano,Ian T T Liu,Jihye Han,Edward R Scheffer Cliff,Aaron S Kesselheim

{"title":"Assessing Outcomes Emerging After Conversion to Regular Approval for Cancer Drug Indications Granted Accelerated Approval, 1992-2021.","authors":"Ariadna Tibau,Alejandra Romano,Ian T T Liu,Jihye Han,Edward R Scheffer Cliff,Aaron S Kesselheim","doi":"10.1093/jnci/djaf195","DOIUrl":"https://doi.org/10.1093/jnci/djaf195","url":null,"abstract":"BACKGROUNDThe FDA's accelerated approval pathway expedites cancer drug approvals based on surrogate measures, while clinical benefit is assessed in post-approval confirmatory trials. Many confirmatory trials also rely on surrogate measures rather than overall survival (OS) or quality of life (QoL). We evaluated how often accelerated approvals demonstrate clinical benefits at the time of conversion to regular approval, and if not, how often OS, QoL, or substantial clinical benefit emerge post-conversion.METHODSThis retrospective cohort study reviewed FDA cancer drug accelerated approvals converted to regular approval (1992-2021), with follow-up through December 2024. We assessed confirmatory trial endpoints (OS and QoL) at conversion, and searched for updated evidence post-conversion. Clinical relevance was assessed using the ESMO-MCBS.RESULTSOf 77 confirmatory trials, 25 (32%) showed OS benefit at conversion; 52 (68%) relied on surrogate measures. After a median 5-year follow-up, OS benefit emerged for 7 (9%) additional indications. QoL benefit was shown in 9 (12%) confirmatory trials at conversion and in 4 (5%) post-conversion. Among 73 (95%) confirmatory trials scoreable by ESMO-MCBS, 34 (47%) met the substantial clinical benefit threshold at conversion. Of the 31 (97%) trials with a survival benefit evaluable by ESMO-MCBS, 19 of 24 (79%) met the threshold at conversion, and 5 of 7 (71%) post-conversion.CONCLUSIONSOnce oncology drugs are converted from accelerated to full approval, new evidence of OS or QoL gains remain rare, underscoring the need to ensure such evidence is available at conversion. Patients should be informed of evidence variability, and the ESMO-MCBS can provide valuable guidance.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144678032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Addressing conceptual and design gaps in the oncology nutrition evidence base during chemotherapy: contributions of the Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes Consortium. 解决化疗期间肿瘤营养证据基础的概念和设计差距：运动和营养干预对改善癌症治疗相关结果的贡献

Journal of the National Cancer Institute Pub Date : 2025-07-18 DOI: 10.1093/jnci/djaf143

Stephanie L E Compton,Heather Wopat,Melissa Lopez-Pentecost,Tanya Agurs-Collins,Justin C Brown,Bette Caan,Wendy Demark-Wahnefried,Joanne W Elena,Leah M Ferrucci,Courtney McGowan,Leah S Puklin,Kathryn H Schmitz,Cynthia A Thomson,Kim Robien,Tracy E Crane,

{"title":"Addressing conceptual and design gaps in the oncology nutrition evidence base during chemotherapy: contributions of the Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes Consortium.","authors":"Stephanie L E Compton,Heather Wopat,Melissa Lopez-Pentecost,Tanya Agurs-Collins,Justin C Brown,Bette Caan,Wendy Demark-Wahnefried,Joanne W Elena,Leah M Ferrucci,Courtney McGowan,Leah S Puklin,Kathryn H Schmitz,Cynthia A Thomson,Kim Robien,Tracy E Crane, ","doi":"10.1093/jnci/djaf143","DOIUrl":"https://doi.org/10.1093/jnci/djaf143","url":null,"abstract":"Evidence to support the development of practice guidelines on nutrition interventions during active cancer treatment is limited despite the established role of nutrition in cancer prevention and long-term survivorship. To address this gap, the National Cancer Institute (NCI) funded the Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes (ENICTO) research consortium. This manuscript focuses on the nutrition-specific work within the ENICTO Consortium. We present a conceptual framework describing how nutritional interventions may enhance cancer treatment tolerance and timely completion of chemotherapy. We also describe how each ENICTO research project selected specific nutrition-related data items and collection methods to test hypotheses outlined in the conceptual framework. Research and consortium-wide projects are described in relation to advancing the scientific rigor of research in the field, including the standardization of nutrition assessment tools and measures. We conclude with a call to action for further research to support the development of evidence-based oncology nutrition practice guidelines relevant to the treatment period within the cancer continuum.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Breast implant illness and the power of national mandatory reporting. 隆胸病与国家强制报告的权力。

Journal of the National Cancer Institute Pub Date : 2025-07-17 DOI: 10.1093/jnci/djaf156

Danielle H Rochlin,Joseph Disa,Jonas A Nelson

引用次数: 0

Prospective associations of diabetes with 15 cancers in 2.2 million UK and Chinese adults. 在220万英国和中国成年人中，糖尿病与15种癌症的前瞻性关联。

Journal of the National Cancer Institute Pub Date : 2025-07-17 DOI: 10.1093/jnci/djaf154

Bowen Liu,Sarah Floud,Ling Yang,TienYu Owen Yang,Huaidong Du,Pang Yao,Kezia Gaitskell,Yiping Chen,Jun Lv,Canqing Yu,DianJianYi Sun,Junshi Chen,Pei Pei,Liming Li,Derrick A Bennett,Zhengming Chen,Gillian K Reeves

{"title":"Prospective associations of diabetes with 15 cancers in 2.2 million UK and Chinese adults.","authors":"Bowen Liu,Sarah Floud,Ling Yang,TienYu Owen Yang,Huaidong Du,Pang Yao,Kezia Gaitskell,Yiping Chen,Jun Lv,Canqing Yu,DianJianYi Sun,Junshi Chen,Pei Pei,Liming Li,Derrick A Bennett,Zhengming Chen,Gillian K Reeves","doi":"10.1093/jnci/djaf154","DOIUrl":"https://doi.org/10.1093/jnci/djaf154","url":null,"abstract":"BACKGROUNDDiabetes has been associated with the risk of numerous cancers but the causal relevance of many of these associations remains unclear.METHODSWe investigated associations between diabetes and risks of 15 cancers using Cox-regression and individual-level data from 2.2 million adults (334,978 incident cancer cases) in three prospective cohorts, UK Biobank (UKB), Million Women Study (MWS), and China Kadoorie Biobank (CKB). The potential impact of residual confounding was assessed by examining changes in diabetes-associated log-HRs after adjustment for key confounders.RESULTSIn combined analyses of individual participant data from three studies, diabetes was positively associated with the risk of 11 cancers, most notably liver (HR = 2.04, 95%CI: 1.87-2.23), pancreas (1.62, 1.48-1.77) and bladder (1.44, 1.29-1.62) cancer. The positive associations of diabetes with cancers of the breast, endometrium, kidney, and oesophageal adenocarcinoma, were substantially attenuated (>50%) after adjustment for confounders. The risks were similar in UK and Chinese populations except for liver cancer, for which the adjusted HR was greater in UK than Chinese adults (2.58 [2.28-2.92] vs 1.61 [1.43-1.83]; Phet=2.5x10-6). For liver cancer, the excess risk associated with diabetes increased with increasing BMI (Ptrend=2.7x10-4) and alcohol intake (Ptrend=0.02). Diabetes was inversely associated with incidence of prostate cancer (0.78 [0.73-0.85]) but positively associated with mortality (1.25 [1.00-1.55]).CONCLUSIONSDiabetes increases the risk of liver, pancreatic, and bladder cancer in UK and Chinese populations. It may also have a lesser effect on stomach, colorectal cancer, and leukaemia but its associations with other cancers could well be explained by confounding and/or other biases.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"109 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144652727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Climate change mitigation and synergies with primary cancer prevention in Europe: time to implement opportunities 欧洲减缓气候变化和与初级癌症预防的协同作用：时机已到

Journal of the National Cancer Institute Pub Date : 2025-07-14 DOI: 10.1093/jnci/djaf182

Joachim Schüz, Isabelle Soerjomataram, Milena Foerster, Oliver Langselius, Sabine Rohrmann, Paolo Vineis, Beatrice Fervers

{"title":"Climate change mitigation and synergies with primary cancer prevention in Europe: time to implement opportunities","authors":"Joachim Schüz, Isabelle Soerjomataram, Milena Foerster, Oliver Langselius, Sabine Rohrmann, Paolo Vineis, Beatrice Fervers","doi":"10.1093/jnci/djaf182","DOIUrl":"https://doi.org/10.1093/jnci/djaf182","url":null,"abstract":"Ten years after the adoption of the treaty on climate change by the 21st Conference of the Parties (COP21) in Paris, implementation of climate change mitigation measures remains a priority and urgency. Same priority and urgency apply to cancer prevention to counter the trend of an increasing cancer burden. The burden is projected to increase worldwide more than 50% during the next 20-25 years, ruling out treatment as the only countermeasure due to overburdened health systems. While the effects of global warming on the cancer burden are highly speculative, synergies of remedial action on climate change and increasing cancer rates have clearer evidence base. These synergies are described for the situation in Europe using the 4th edition of the European Code against Cancer (ECAC) for recommendations on cancer prevention and the 2030 breakthroughs for climate change mitigation by the United Nations Climate Change (UNCC) High-Level Champions Climate Solutions Implementation Roadmap. ECAC’s recommendations on healthy body weight, physical activity, reduced meat consumption, avoiding too much sun, and reducing air pollution, align well with many of the 2030 breakthrough recommendations. Those are on healthier food including limiting meat consumption, on cleaner air through reducing transportation and through in general reducing carbon, methane and other emissions, and on mitigating temperature rise. Campaigns combining climate change mitigation with cancer prevention have the potential to encourage individuals, community groups, and policy-makers to empower the implementation of measures to counter global warming and towards a world where fewer people get cancer.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"49 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144645527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Aprepitant use during chemotherapy and association with survival in women with early breast cancer 早期乳腺癌患者化疗期间阿瑞吡坦的使用及其与生存率的关系

Journal of the National Cancer Institute Pub Date : 2025-07-14 DOI: 10.1093/jnci/djaf178

Edoardo Botteri, Sarah Hjorth, Fabio Conforti, Vincenzo Bagnardi, Bettina K Andreassen, Nathalie C Støer, Sameer Bhargava, Giske Ursin, Sara Gandini, Erica K Sloan, Aeson Chang

{"title":"Aprepitant use during chemotherapy and association with survival in women with early breast cancer","authors":"Edoardo Botteri, Sarah Hjorth, Fabio Conforti, Vincenzo Bagnardi, Bettina K Andreassen, Nathalie C Støer, Sameer Bhargava, Giske Ursin, Sara Gandini, Erica K Sloan, Aeson Chang","doi":"10.1093/jnci/djaf178","DOIUrl":"https://doi.org/10.1093/jnci/djaf178","url":null,"abstract":"Background Preclinical studies have shown that aprepitant, an antiemetic used to prevent chemotherapy-induced nausea and vomiting, slows mammary tumor growth and progression. Here, we evaluated the association between aprepitant and survival in a large cohort of women with early breast cancer. Methods Using linked nationwide registry data, we identified 13,811 women diagnosed with early breast cancer between 2008 and 2020 in Norway, who received chemotherapy and antiemetics. Women were followed for metastasis and death from one year after diagnosis until the end of 2021. To evaluate the association between aprepitant use and distant disease-free survival (DDFS) and breast cancer-specific survival (BCSS) we used Cox regression models, controlling for tumor and patient characteristics, chemotherapy regimens, and use of other antiemetics. Results During chemotherapy, 7,047 (51%) women were supplied with aprepitant. Overall, aprepitant use was associated with better DDFS (HRDDFS 0.89; 95%CI 0.79-1.00) and BCSS (HRBCSS 0.83; 95%CI 0.71-0.97). The survival advantage was specific to women with non-luminal breast cancer (HRDDFS 0.69; 95%CI 0.56-0.83; HRBCSS 0.64; 95%CI 0.51-0.81) and was strongest in women with triple negative breast cancer (TNBC)(HRDDFS 0.66; 95%CI 0.53-0.83; HRBCSS 0.61; 95%CI 0.47-0.80). In women with non-luminal breast cancer, longer durations of aprepitant use were associated with increasingly favorable survival outcomes (DDFS: Ptrend=0.002; BCSS: Ptrend=0.016). Supply of other antiemetics of different drug classes was not associated with survival. Conclusions Aprepitant use during chemotherapy treatment was associated with better prognosis for women with non-luminal early breast cancer, in particular TNBC. Long-term clinical trials are required to confirm these findings.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"109 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144629829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A prediction model for metachronous colorectal cancer: development and validation 异时性结直肠癌预测模型的建立与验证

Journal of the National Cancer Institute Pub Date : 2025-07-14 DOI: 10.1093/jnci/djaf191

Ye Zhang, Amalia Karahalios, Aung Ko Win, Enes Makalic, Alex Boussioutas, Daniel D Buchanan, Stephanie L Schmit, N Jewel Samadder, Finlay A Macrae, Mark A Jenkins

{"title":"A prediction model for metachronous colorectal cancer: development and validation","authors":"Ye Zhang, Amalia Karahalios, Aung Ko Win, Enes Makalic, Alex Boussioutas, Daniel D Buchanan, Stephanie L Schmit, N Jewel Samadder, Finlay A Macrae, Mark A Jenkins","doi":"10.1093/jnci/djaf191","DOIUrl":"https://doi.org/10.1093/jnci/djaf191","url":null,"abstract":"Background Being able to estimate a colorectal cancer case’s risk of metachronous colorectal cancer could enable risk-appropriate surveillance. The aim was to develop a risk prediction model to estimate individual 10-year risk of metachronous colorectal cancer following a colorectal cancer diagnosis. Methods A cohort of population-based colorectal cancer cases were recruited soon after their diagnosis between 1997 and 2012 from America, Canada, and Australia. Cox regression with the least absolute shrinkage and selection operator penalization was used to identify factors that predicted the risk of a new primary colorectal cancer diagnosed at least one year after the initial colorectal cancer. Potential predictors included demography, anthropometry, lifestyle factors, comorbidities, personal and family cancer history, medication use, and diagnosis age and pathological features of the first colorectal cancer. Internal validation through bootstrapping was used to evaluate the discrimination and calibration. Results 6,085 colorectal cancer cases were included. 138 (2.3%) were diagnosed with metachronous colorectal cancer over a median of 12 years (interquartile range 5 − 17 years). Metachronous colorectal cancer risk was predicted by body mass index, smoking, physical activity, family history of cancer and synchronous colorectal cancer, stage, grade, histological type and DNA mismatch repair status and diagnosis age of the first colorectal cancer. The model was valid with a c-statistic of 0.65 (95% CI: 0.63 − 0.68) and a calibration slope of 0.873 (standard deviation: 0.087). Conclusions Metachronous colorectal cancer can be predicted with reasonable accuracy by this prediction model that consists of clinical variables collected as part of routine practice.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144645389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

U.S. cancer deaths prevented due to survival improvements stratified by extent of disease, 2010-2019 2010-2019年，按疾病程度分层的生存改善预防了美国癌症死亡

Journal of the National Cancer Institute Pub Date : 2025-07-14 DOI: 10.1093/jnci/djaf192

Meredith S Shiels, Neal D Freedman, Anika T Haque, Amy Berrington de González, Stanley Lipkowitz, Douglas R Lowy, Ruth M Pfeiffer

{"title":"U.S. cancer deaths prevented due to survival improvements stratified by extent of disease, 2010-2019","authors":"Meredith S Shiels, Neal D Freedman, Anika T Haque, Amy Berrington de González, Stanley Lipkowitz, Douglas R Lowy, Ruth M Pfeiffer","doi":"10.1093/jnci/djaf192","DOIUrl":"https://doi.org/10.1093/jnci/djaf192","url":null,"abstract":"Background Progress against cancer mortality has been driven by primary prevention, early detection, and cancer treatment. We estimated the number of cancer deaths that were avoided due to stage-specific improvements in cancer survival among patients diagnosed in 2010-2019 followed through 2020. Methods We utilized cancer incidence data from 17 Surveillance, Epidemiology and End Results (SEER) cancer registries during 2004-2019. We estimated the number of cancer deaths prevented due to cancer- and stage-specific survival improvements (based on SEER summary stage) as the observed minus expected number of cancer deaths through 2020. We calculated the expected number of cancer deaths from estimated cumulative incidence models setting the calendar year effect to 2009. Results During 2010-2019, there were 3,310,270 incident cancers and 966,733 cancer deaths through 2020 in SEER-17. Improvements in stage-specific cancer survival resulted in a 4.7% (95%CI -5.3%, -4.2%) decline in cancer deaths in females (22,874 fewer deaths) and a 4.4% (95%CI -4.9%, -3.9%) decline in males (23,198 fewer deaths) in SEER-17 regions, corresponding to approximately 173,900 fewer cancer deaths in the full U.S. population. The largest absolute declines were for lung and liver cancers, while the largest relative declines were observed for melanoma and leukemia. Cancer deaths prevented were not statistically significant for colorectal or prostate cancers. All statistical tests were two-sided. Conclusions Stage-specific survival gains, reflecting treatment advances and improved access to cancer treatment from 2010-2019, resulted in an estimated 173,900 fewer cancer deaths among US cancer patients diagnosed during this time period.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144645465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Polygenic risk of coronary artery disease for long-term survivors of breast cancer 乳腺癌长期幸存者冠状动脉疾病的多基因风险

Journal of the National Cancer Institute Pub Date : 2025-07-14 DOI: 10.1093/jnci/djaf189

Gordon P Watt, Anne S Reiner, Xiang Shu, Kathleen E Malone, Julia A Knight, Esther M John, Eric J Chow, Charles F Lynch, Lene Mellemkjær, Meghan Woods, Xiaolin Liang, Anh Phong Tran, Jung Hun Oh, Andriy Derkach, Jonine L Bernstein

{"title":"Polygenic risk of coronary artery disease for long-term survivors of breast cancer","authors":"Gordon P Watt, Anne S Reiner, Xiang Shu, Kathleen E Malone, Julia A Knight, Esther M John, Eric J Chow, Charles F Lynch, Lene Mellemkjær, Meghan Woods, Xiaolin Liang, Anh Phong Tran, Jung Hun Oh, Andriy Derkach, Jonine L Bernstein","doi":"10.1093/jnci/djaf189","DOIUrl":"https://doi.org/10.1093/jnci/djaf189","url":null,"abstract":"Aim Cardiovascular disease is a leading cause of death for long-term breast cancer survivors. We evaluated whether a polygenic risk score for coronary artery disease (CAD-PRS) was associated with the risk of incident CAD for survivors of unilateral or contralateral breast cancer. Methods The study included 1,307 women with breast cancer first diagnosed at age &lt;55 years who participated in the WECARE Follow-up Study. The CAD-PRS was based on a PRS developed and validated in a separate population. We modelled the association between incident CAD and the CAD-PRS, adjusting for age, CAD risk factors, first (and second) breast cancer treatment, study recruitment phase, and genetic population stratification. We also explored whether the risk of CAD depended on interactions between the CAD-PRS and cardiotoxic cancer treatment. Results There were 65 incident CAD diagnoses reported at a median of 16 years after breast cancer diagnosis. Participants with CAD-PRS≥median had a 2.48-times increased risk of CAD (95%CI = 1.44-4.29) relative to participants with CAD-PRS&lt;median. Anthracycline-based chemotherapy was associated with increased CAD risk (HR = 2.04, 95%CI = 1.04-3.98), and the association was not modified by the CAD-PRS. The association between incident CAD and left-sided RT was increased for those with CAD-PRS≥median (HR = 2.90, 95% CI = 1.26-6.68), but not for those with CAD-PRS&lt;median (HR = 0.96, 95% CI 0.32-2.88). There was evidence of super-additive interaction between the CAD-PRS and left-sided RT (relative excess risk due to interaction = 2.06, 95% CI 0.05-4.06). Conclusions A genome-wide CAD-PRS was associated with non-fatal CAD risk for long-term breast cancer survivors, providing potential utility for personalized cardiovascular care, particularly after RT.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"679 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144639767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0